**Core tip:** Liver stiffness measurement (LSM) is said to be exaggerated in nonalcoholic fatty liver disease (NAFLD). We investigated the role of controlled attenuation parameter (CAP), a means of measuring steatosis noninvasively, in predicting liver fibrosis by LSM in 184 biopsy proven nonalcoholic steatohepatitis patients. The optimum LSM cutoff for Kleiner fibrosis stage (F) ≥ 2 reflecting CAP values showed higher cutoff with increased CAP tertile (LSM, 8.05 kPa for lower CAP tertile, 9.35 kPa for middle, 10.45 kPa for high CAP tertile). Therefore, we suggest that interpretation of LSM in patients with NAFLD should take CAP scores into account in order to avoid unnecessary liver biopsy.

INTRODUCTION
============

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease around worldwide. The spectrum of NAFLD ranges from simple steatosis without evidence of liver injury to nonalcoholic steatohepatitis (NASH) with or without liver fibrosis\[[@B1]\]. Although the natural history of NAFLD requires further investigation, studies demonstrate that the severity of liver fibrosis is the most important determinant of mortality and morbidity in patients with NAFLD\[[@B2]-[@B4]\]. Patients with significant liver fibrosis \[Kleiner classification fibrosis stage (F) ≥ 2\] showed decreased survival compared to those with no or minimal fibrosis (F0-1)\[[@B4]\]. NAFLD may progress from simple steatosis to NASH with fibrosis, and estimation of severity of liver fibrosis is critical not only for the initial workup but also for follow- up\[[@B5]\].

Although liver biopsy is considered the gold standard for assessing the severity of fibrosis\[[@B6]\], it is an invasive procedure that might not be practical to perform sequentially. Instead, the liver stiffness measurement (LSM), obtained by transient elastograpy (TE) is a useful noninvasive means of assessing liver fibrosis. LSM values are well correlated with the biopsy determined severity of fibrosis\[[@B7]-[@B9]\]. However, the diagnostic performance of LSM is known to be affected by obesity and the severity of steatosis, which are closely associated with NAFLD, resulting in overestimation of the LSM in patients with NAFLD\[[@B10]-[@B12]\]. Recently, FibroScan, a type of TE, has been equipped with controlled attenuation parameter (CAP), software to enable noninvasive quantification of hepatic steatosis. The CAP value was strongly correlated with the histologically assessed percentage of liver fat in patients with NAFLD, but is susceptible to interference by liver fibrosis\[[@B13]\]. However, CAP may enhance the accuracy of TE measured LSM in patients with NAFLD\[[@B14]\]. We evaluated the role of the CAP value in predicting the liver fibrosis stage based on LSM in patients with biopsy proven NASH.

MATERIALS AND METHODS
=====================

Study design
------------

This retrospective study involved patients with biopsy proven NASH evaluated at Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. Liver biopsy was performed to confirm the diagnosis of NASH in patients with ultrasound findings of fatty liver and persistent (\> 6 mo) elevation of the alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level without excessive alcohol consumption (30 g/day in men and 20 g/day in women). Patients in whom liver stiffness was evaluated within 1 mo before the liver biopsy were included in the analysis. The exclusion criteria were as follows: (1) Liver disease of other or mixed etiology (such as hepatitis B infection, hepatitis C infection, alcohol abuse, autoimmune liver disease, Wilson's disease, or drug-induced liver disease); (2) LSM evaluated while the AST or ALT level was more than fivefold the upper limit of normal (ULN); (3) Hepatocellular carcinoma; (4) Advanced liver cirrhosis (Child-Turcotte-Pugh B and C); (5) Previous treatment with steatosis-inducing drugs such as tamoxifen, aromatase inhibitor, valproic acid, amiodarone or corticosteroid; (6) Human immunodeficiency virus infection; (7) Active intravenous drug addiction or use of cannabis; and (8) Insufficient clinical data.

This study was performed in accordance with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Institutional Review Board (IRB) of Gangnam Severance Hospital (permit no: 3-2019-0010). The requirement for written informed consent was exempted by the IRB since the database was accessed only for analysis purposes and the patients' personal information was anonymized by coding.

Clinical assessment
-------------------

Demographic, clinical and anthropometric data were collected at the time of liver biopsy. Hypertension was defined as use of antihypertensive medication and type 2 diabetes mellitus was considered present if the fasting glucose level was ≥ 126 mg/dL or antidiabetic agents were being used. Body mass index (BMI) was calculated as body weight in kilogram divided by the square of height in meters, and a BMI ≥ 25 kg/m^2^ was considered to indicate obesity based on the criteria used in the Asian-Pacific region\[[@B15]\].

Liver stiffness measurement
---------------------------

TE was performed using a FibroScan (Echosens, Paris, France), medical device, with a standard probe. Only LS values with at least 10 valid measurements, a success rate of at least 60%, and an interquartile range-to-median ratio of \< 30% were considered reliable, as suggested by previous studies\[[@B16],[@B17]\]. In addition, patients in whom LS was measured while the AST or ALT \> 5 × ULN was present, were excluded from the analysis due to possible exaggerated LSM values as previous studies demonstrated\[[@B18],[@B19]\]. The baseline LSM was obtained within 1 month before liver biopsy. The follow-up LSM was performed after 12 mo of NASH treatment with daily dose of 15 mg pioglitazone, peroxisome proliferator-activated receptor (PPAR)-γ agonist, or 300 mg/day ursodeoxycholic acid (UDCA) following liver biopsy.

Histologic assessment
---------------------

A single liver-dedicated expert pathologist, blinded to the patients' identity, performed the histologic analysis. A ≥ 15-mm-long biopsy specimen or the presence of at least 10 complete portal tracts was considered adequate for the analysis\[[@B20]\]. NASH was diagnosed according to the NASH Clinical Research Network System, and was defined as the presence of ≥ 5% hepatic steatosis and inflammation with hepatocyte injury such as ballooning with or without fibrosis\[[@B21]\].

Statistical analysis
--------------------

All statistical tests were performed using IBM SPSS Statistics 22.0 (IBM, Armonk, NY, United States). Continuous variables are expressed as means ± standard deviation (SD) or medians (range). The area under the receiver-operating characteristic (ROC) curve was calculated to reflect the overall accuracy of LSM for diagnosing significant fibrosis (F2-4). Categorical variables were compared by using two-sided χ^2^-test (or Fisher's exact test, or McNemar test, as appropriate) and continuous variables by independent or Mann-Whitney test as appropriate. A paired *t* test was performed to evaluate changes in LSM. A two-sided *P* value of \< 0.05 was considered indicative of statistical significance.

RESULTS
=======

Patients
--------

From January 2010 to December 2017, 325 patients underwent liver biopsy and LSM assessed due to suspicion of NASH. Among them, 184 patients met the inclusion and exclusion criteria and were thus included in the analysis. The baseline characteristics of the 184 patients with NASH are listed in Table [1](#T1){ref-type="table"}.

###### 

Demographic, clinical, biochemical and histological characteristics of 184 patients with nonalcoholic steatohepatitis

  **Variable**                               **NAFLD (*n* = 184)**
  ------------------------------------------ -----------------------
  Age (yr)                                   44.6 ± 14.5
  Male gender                                127 (69.0%)
  Body mass index, median (range, kg/m^2^)   29.3 (19.8-44.5)
  Body mass index ≥ 25 kg/m^2^               156 (84.8%)
  Diabetes                                   69 (37.5%)
  Hypertension                               54 (29.3%)
  Hyperlipidemia                             75 (40.8%)
  Fasting glucose (mg/dL)                    117.9 ± 32.9
  HDL cholesterol (md/dL)                    47.1 ± 11.8
  Triglycerides (mg/dL)                      193.8 ± 127.5
  LDL cholesterol (mg/dL)                    131.7 ± 31.3
  Alanine aminotransferase (U/L)             92.4 ± 68.1
  Aspartate aminotransferase (U/L)           67.3 ± 39.2
  Gamma glutamyltransferase (U/L)            74.1 ± 86.7
  Platelet (× 1000/mm^3^)                    244.8 ± 58.6
  Albumin (g/dL)                             4.5 ± 0.3
  Liver stiffness (kPa)                      10.9 ± 4.9
  Stiffness IQR (kPa)                        1.8 ± 3.3
  CAP (dB/m)                                 320.9 ± 37.1
  Lower tertile                              223-310
  Middle tertile                             311-339
  Higher tertile                             340-400
  CAP IQR (dB/m)                             24.7 ± 9.5
  Histology at biopsy                        
  Steatosis grade                            
  1 (5%-33%)                                 44 (23.9%)
  2 (34%-66%)                                81 (44.0%)
  3 (\> 66%)                                 59 (32.1%)
  Stage of fibrosis (Kleiner)                
  0                                          20 (10.9%)
  1                                          84 (45.7%)
  2                                          53 (28.8%)
  3                                          21 (11.4%)
  4                                          6 (3.3%)

Data are expressed as the mean ± standard deviation, median (range) or number (%). HDL: High-density lipoprotein; LDL: Low-density lipoprotein; CAP: Controlled attenuation parameter; IQR: Interquartile range; NAFLD: Nonalcoholic fatty liver disease.

Assessment of steatosis using CAP
---------------------------------

Among the 184 patients with biopsy proven NASH, the distribution of the histologically assessed steatosis grade (S) was as follows: S1, *n* = 44 (2.9%); S2, *n* = 81 (44.0%); S3, *n* = 59 (32.1%) (Figure [1](#F1){ref-type="fig"}). The CAP scores were significantly different between S1 and S2-S3 (*P* \< 0.001). However, no significant difference was detected between S2 and S3 (*P* = 0.075). The ROC curve showed the optimum CAP cutoff for ≥ S2 was 313.5 dB/m \[area under the curve (AUC), 0.736; sensitivity, 72.9%; specificity, 63.6%\]. On the other hands, the accuracy dropped to an AUC of 0.656 for S3, with a cutoff of 323.5 dB/m (sensitivity 64.4%; specificity 55.2%).

![Distribution of controlled attenuation parameter scores according to histologically assessed steatosis grades (S). CAP: Controlled attenuation parameter.](WJG-25-4959-g001){#F1}

Factors associated with LSM
---------------------------

LSM significantly increased with the histologically detected fibrosis stage (F0, 7.5 ± 2.1; F1, 9.8 ± 2.7; F2, 11.8 ± 4.9; F3, 15.4 ± 6.9; and F4, 20.3 ± 8.8 kPa) (*P* \< 0.001). The ROC curve showed that the optimum LSM cutoff for ≥ F2 was 8.95 kPa (AUC, 0.730; sensitivity, 72.5%; specificity, 65.4%). According to univariate and multivariate analyses, the CAP values and pathologically detected fibrosis stage was significantly associated with LSM (Table [2](#T2){ref-type="table"}).

###### 

Univariate and multivariate analysis of factors associated with liver stiffness measurements as continuous variable in 184 patients with nonalcoholic steatohepatitis by linear regression analysis

                         **Univariate analysis**   **Multivariate analysis**                                                               
  ---------------------- ------------------------- --------------------------- ------------------------------------------ -------- ------- ------------------------------------------
  Age (yr)               0.053                     0.025                       0.037[a](#T2FN1){ref-type="table-fn"}      0.017    0.022   0.451
  Male gender            0.957                     0.792                       0.228                                                       
  BMI (kg/m^2^)          -0.032                    0.083                       0.700                                                       
  CAP (dB/m)             0.022                     0.010                       0.026[a](#T2FN1){ref-type="table-fn"}      0.041    0.009   \< 0.001[b](#T2FN2){ref-type="table-fn"}
  LS IQR (kPa)           0.329                     0.109                       0.003[b](#T2FN2){ref-type="table-fn"}      0.294    0.022   0.451
  Histology at biopsy                                                                                                                      
  Steatosis              -0.895                    0.490                       0.069                                      -0.532   0.445   0.233
  Lobular inflammation   1.134                                                 0.082                                      0.152            0.776
                         1.366                     0.650                       0.008[b](#T2FN2){ref-type="table-fn"}      0.638    0.532   0.131
  Ballooning             2.769                     0.509                       \< 0.001[b](#T2FN2){ref-type="table-fn"}   2.665    0.421   \< 0.001[b](#T2FN2){ref-type="table-fn"}
  Fibrosis                                         0.331                                                                           0.344   

*P* \< 0.05;

*P* \< 0.01. SE: Standard error; BMI: Body mass index; CAP: Controlled attenuated parameter; LS IQR: Liver stiffness interquartile range.

Although there were significant differences in CAP scores between S1 and S2-S3, no cutoff could differentiate S3 from S2. S2 and S3 accounted for the majority of the patients (76.1%, 140/184). Furthermore, in a multivariate analysis, the CAP value, but not the pathologically detected steatosis grade, was associated with LSM. Therefore, the variations in the LSM value for each stage of liver fibrosis was evaluated according to arbitrary CAP tertiles (lower, 223-310; middle, 311-339; high 340-400 dB/m) (Figure [2](#F2){ref-type="fig"}). For F0-1, LSM values significantly increased at high CAP tertile (*P* = 0.001) (Figure [2A](#F2){ref-type="fig"}). For F2, LSM values were higher for the middle and high CAP tertiles (*P* = 0.027) (Figure [2B](#F2){ref-type="fig"}). However, the LSM values did not differ significantly according to CAP tertile in patients with NASH and advanced fibrosis (F3-4) (*P* = 0.752) (Figure [2C](#F2){ref-type="fig"}).

![Distribution of liver stiffness values within the same Kleiner fibrosis stages (F0-4) in different controlled attenuation parameter tertiles. A: F0-1; B: F2; C: F3-4. CAP: Controlled attenuation parameter.](WJG-25-4959-g002){#F2}

When cutoff of 8.95 kPa was used to diagnose significant fibrosis (F ≥ 2), positive predictive values in lower, middle and high CAP tertiles was 21/31 (67.7%), 19/32 (59.4%) and 23/49 (46.9%), respectively. False positive rates increased with increasing CAP tertile (Figure [3A](#F3){ref-type="fig"}). However, when different cutoffs were used for each CAP tertile, differences in false positive rates among different CAP tertile were reduced and the false positive rate in high CAP tertile decreased (Figure [3B](#F3){ref-type="fig"}). ROC curves showed that the optimum LSM cutoff for diagnosis of F ≥ 2 was 8.05 kPa (AUC, 0.682; sensitivity, 73.5%; specificity 51.7%) for the lower CAP tertile, LSM of 9.35 kPa (AUC, 0.843; sensitivity, 90.5%; specificity 71.8%) for the middle CAP tertile, and LSM of 10.55 kPa (AUC 0.682; sensitivity, 76.0%; specificity 52.8%) for high CAP tertile.

![False-positive rates when evaluating liver fibrosis stages by liver stiffness measurements. A: The cutoff of 8.95 kPa for detecting Kleiner fibrosis stage (F) ≥ 2 was applied in all controlled attenuation parameter (CAP) tertiles; B: Different cutoffs were applied according to CAP tertiles. CAP: Controlled attenuation parameter; LSM: Liver stiffness measurements.](WJG-25-4959-g003){#F3}

Effect of PPAR-γ agonist on follow up LSM
-----------------------------------------

Among the 184 patients with biopsy proven NASH, 130 patients had LS measured 1 year after liver biopsy and were treated with PPAR-γ agonist (pioglitazone) 15 mg/day (*n* = 80) or UDCA 300 mg/day (*n* = 50). Regarding the baseline characteristics, there was no significant difference in BMI, LS value or CAP score between the two groups (Table [3](#T3){ref-type="table"}). However, the pioglitazone group had higher rates of DM and hypertension (*P* = 0.048, *P* = 0.049, respectively).

###### 

Demographic, clinical, biochemical and histological characteristics of patients with nonalcoholic steatohepatitis under either pioglitazone or ursodeoxycholic acid

  **Variable**                       **Pioglitazone group** **(*n* = 80)**   **UDCA group** **(*n* = 50)**   ***P* value**
  ---------------------------------- --------------------------------------- ------------------------------- ---------------------------------------
  Age (yr)                           47.6 ± 14.5                             44.9 ± 14.5                     0.303
  Male gender                        60 (75.0%)                              30 (60.0)                       0.071
  Body mass index ≥ 25 kg/m^2^       66 (82.5%)                              41 (82.0%)                      0.942
  Diabetes                           38 (47.5%)                              15 (30.0)                       0.048[a](#T3FN1){ref-type="table-fn"}
  Hypertension                       29 (36.2%)                              10 (20.0%)                      0.049[a](#T3FN1){ref-type="table-fn"}
  Hyperlipidemia                     36 (45.0%)                              26 (52.0%)                      0.437
  Fasting glucose (mg/dL)            121.3 ± 34.5                            112.5 ± 24.1                    0.090
  HDL cholesterol (md/dL)            47.9 ± 10.0                             47.7 ± 14.1                     0.923
  Triglycerides (mg/dL)              199.5 ± 147.7                           185.9 ± 105.2                   0.590
  LDL cholesterol (mg/dL)            130.5 ± 29.4                            136.4 ± 34.8                    0.435
  Alanine aminotransferase (U/L)     103.0 ± 76.1                            74.6 ± 48.7                     0.011[a](#T3FN1){ref-type="table-fn"}
  Aspartate aminotransferase (U/L)   70.2 ± 40.5                             65.7 ± 42.8                     0.554
  Gamma glutamyltransferase (U/L)    63.9 ± 61.3                             62.3 ± 41.8                     0.856
  Platelet (× 1000/mm^3^)            229.8 ± 54.8                            253.2 ± 54.4                    0.019[a](#T3FN1){ref-type="table-fn"}
  Albumin (g/dL)                     4.5 ± 0.3                               4.5 ± 0.3                       0.866
  Liver stiffness (kPa)              11.7 ± 4.8                              10.5 ± 5.4                      0.183
  Stiffness IQR (kPa)                2.2 ± 4.7                               1.4 ± 0.9                       0.387
  CAP (dB/m)                         318.2 ± 37.9                            319.3 ± 37.1                    0.873
  CAP IQR (dB/m)                     25.2 ± 9.0                              23.0 ± 10.1                     0.216
  Fibrosis score (Kleiner)                                                                                   0.017[a](#T3FN1){ref-type="table-fn"}
  F0                                 2 (2.5%)                                9 (18.0%)                       
  F1                                 41 (51.2%)                              21 (42.0%)                      
  F2                                 24 (30.0%)                              15 (30.0%)                      
  F3-4                               13 (16.3%)                              5 (10.0%)                       

Data are expressed as the mean ± standard deviation or median (range) or number (%),

*P* \< 0.05. UDCA: Ursodeoxycholic acid; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; CAP: Controlled attenuation parameter; IQR: Interquartile range.

The patients treated with pioglitazone demonstrated a decreased LSM value after 1- year of treatment (*P* \< 0.001), when that in UDCA-treated patients did not change significantly (*P* = 0.068) (Figure [4](#F4){ref-type="fig"}). The CAP values did not show significant changes after treatment with pioglitazone (318.2 ± 37.9 *vs* 313.2 ± 41.5 dB/m, *P* = 0.197) or UDCA (319.3 ± 37.1 *vs* 309.2 ± 38.2 dB/m, *P* = 0.057). Changes in the proportion of patients with LSM suggesting significant fibrosis (F ≥ 2) were assessed separately in the pioglitazone and UDCA groups according to the LSM cutoffs for each CAP tertile, that were obtained from the analysis with 184 patients. Among the patient with lower CAP tertile (223-309 dB/m), those treated with pioglitazone showed a decreased proportion of high LSM values (F ≥ 2) but the proportion of high LSM values did not change significantly among the patients treated with UDCA (Figure [4A](#F4){ref-type="fig"}). Similar results were noted in patients with middle (310-332 dB/m) and high CAP tertile (333-400 dB/m) (Figure [4B](#F4){ref-type="fig"} and [C](#F4){ref-type="fig"}).

![Change in the proportion of liver stiffness measurements predicting significant liver fibrosis, Kleiner fibrosis stage F ≥ 2, after 1-year of pioglitazone or ursodeoxycholic acid treatment. A: In the lower controlled attenuation parameter (CAP) tertile; B: In the middle CAP tertile; C: In the high CAP tertile. The liver stiffness measurements (LSM) cutoff values for F ≥ 2 are derived from the analysis 184 patients with biopsy proven nonalcoholic steatohepatitis after considering different CAP scores in tertiles. The changes in LSM values are compared by paired *t*-test. CAP: Controlled attenuation parameter; LSM: Liver stiffness measurements.](WJG-25-4959-g004){#F4}

DISCUSSION
==========

This study of 184 patients with biopsy proven NASH demonstrated that high CAP scores are associated with increased LSM values at the same fibrosis stage, resulting in overestimation of liver fibrosis. Lower positive predictive values were noted in patients in the high CAP tertile, particularly those with F0-2. Therefore, higher LSM cutoffs might be useful for identifying significant fibrosis in patients with NAFLD and high CAP values. Although a "high CAP cutoff value" had yet to be defined, the cutoff for the high CAP tertile in this study was 330-340 dB/m.

Two prospective cohort studies on the natural history of NAFLD proposed that the severity of liver fibrosis is the most important predictor of liver-related complications as well as survival in patients with NAFLD\[[@B2],[@B3]\]. In addition, recent studies suggested that only the severity of fibrosis is an important prognostic factor for NAFLD, and is independent of NASH and the severity of inflammation\[[@B4],[@B22]\]. These studies investigated the prognostic value of the baseline liver fibrosis stage, and one also assessed the progression of liver fibrosis in patients with NAFLD\[[@B5]\]. Therefore, when sequential liver biopsy is not practical, accurate prediction of fibrosis stage using noninvasive methods is important. To reduce the effect of hepatic steatosis, as indicated by CAP scores, on the prediction of fibrosis based on LSM, we calculated the cutoff values for significant fibrosis in according to CAP tertile. We applied arbitrary CAP tertiles since the CAP score did not accurately differentiate S2 from S3 which accounted for the majority of the patients. Also, CAP reportedly cannot differentiate adjacent grades of steatosis with high precision\[[@B23]\]. As a noninvasive means of steatosis measurement, magnetic resonance imaging (MRI)-proton density fat traction (PDFF) is reported to be more accurate for predicting hepatic steatosis compared to CAP\[[@B24]\]. Magnetic resonance elastography (MRE) has the highest diagnostic accuracy for staging fibrosis in patients with NAFLD. However, both MRI-PDFF and MRE are MRI-based tools that require more space and more costly than FibroScan with CAP\[[@B25]\].

Cutoff values according to CAP tertile were applied to estimate the effect of pioglitazone and UDCA on the LSM values at the 1-year follow up. Treatment with pioglitazone reduced LSM-estimated proportion of significant fibrosis. However, the CAP score did not change significantly after pioglitazone or UDCA administration. In recent NAFLD practice guidance, pioglitazone and 800 IU/day vitamin E are recommended to improve liver histology in patients with NASH\[[@B26]\]. The 184 patients from which the LSM cutoff values for significant fibrosis were estimated included 130 patients treated with pioglitazone or UDCA. Although pioglitazone improved the LSM value, the utility of this result is limited by several factors. Ironically, the accuracy of LSM cutoff determined based on the CAP score cannot be validated without follow-up biopsy after pioglitazone or UDCA treatment in patients with NASH. Therefore, studies involving paired liver biopsies are needed, until more reliable LSM standards for NAFLD are established. Secondly, being a retrospective, observational study, the baseline demographic parameters of the pioglitazone and UDCA-treated groups were not matched. Patients treated with pioglitazone were more likely to be diabetic and hypertensive which are important elements of metabolic syndrome. Among NAFLD patients with fibrosis progression, 80% were diabetic, suggesting that diabetes promotes the progression of NASH\[[@B5]\]. Although it involved a larger number of patients with diabetes, our study showed that pioglitazone resulted in a reduced proportion of patients with high LSM values compared to UDCA. However, the sample size was too small to reach a definite conclusion. Finally, unlike previous investigations of the effect of pioglitazone on NASH, the patients in this study received low dose of pioglitazone (15 mg/day). Two randomized studies of the effect of pioglitazone on NASH prescribed pioglitazone 30 mg or 45 mg daily to patients with NASH\[[@B27],[@B28]\]. The mean BMIs of the patients in these previous studies were about 33-35 kg/m^2^, compare to 29.2 ± 4.5 kg/m^2^ in this study, and the lower dose of pioglitazone may have been effective due to the lower BMI of our patients. Further studies investigating smaller doses of pioglitazone on patients with NASH are needed to verify our results.

In conclusion, LSM in patients with NASH may overestimate the liver fibrosis stage, particularly in those with high CAP values. Interpretation of LSM results taking into consideration the simultaneously measured CAP scores may prevent the performance of unnecessary liver biopsy in patients with NAFLD.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

In nonalcoholic fatty liver disease (NAFLD), studies demonstrate that the severity of liver fibrosis is the most important determinant of the disease prognosis. Although liver biopsy is considered the gold standard for identifying fibrosis stage, it is an invasive procedure, and liver stiffness measurement (LSM) is widely preformed as a noninvasive means. However, LSM tends to overestimate fibrosis stage in NAFLD.

Research motivation
-------------------

Controlled attenuation parameter (CAP), provided by LSM device, has been introduced for noninvasive quantification of hepatic steatosis. It also has been suggested that CAP may contribute in enhancing the accuracy of transient elastography measured LSM in patients with NAFLD.

Research objectives
-------------------

Our aim was to determine the role of CAP values in predicting liver fibrosis stages by LSM.

Research methods
----------------

This retrospective study involves 184 patients with biopsy proven nonalcoholic steatohepatitis (NASH), seen at a tertiary hospital in Seoul, Republic of Korea between 2010 and 2017. These patients had LSM and CAP evaluated within one month before the liver biopsy. Liver stiffness and CAP scores were measured by the FibroScan (Echosens, Paris, France), a medical device, using a standard probe. The patients in whom liver stiffness was measured when aspartate aminotransferase or alanine aminotransferase level was more than fivefold the upper limit of normal were excluded from the analysis due to the possibility of exacerbated LSM values. From 184 patients, 130 patients had 1-year follow-up LSM and analyzed for the changes of LSM after pioglitazone or ursodeoxycholic acid (UDCA) treatment.

Research results
----------------

Among 184 NASH patients with liver biopsy, histologically assessed steatosis grade (S) was distributed as follows: S1, *n* = 44 (2.9%); S2, *n* = 81 (44.0%); S3, *n* = 59 (32.1%). CAP scores were significantly different between S1 and S2-S3 (P \< 0.001). However, no significant difference was found between S2 and S3 (*P* = 0.075). LSM significantly increased in accordance with the liver biopsy detected fibrosis stage (*P* \< 0.001). After multivariate analysis, CAP value along with pathologically detected fibrosis stages was identified as a significant factor associated with LSM. Since our assessment showed that no reliable cutoff was demonstrated to differentiate S3 from S2 and 76.1% (140/184) of our study patients were either S2 or S3, variations of LSM within the same stage of liver fibrosis was evaluated according to the arbitrary CAP tertiles (lower 223-310, middle 311-339, high 340-400 dB/m). In Kleiner fibrosis stage F0 - 1, LSM values increased at high CAP tertile (*P* = 0.001), and in F2, at middle and high tertile (*P* = 0.027). No difference was noticed in F3-4 (*P* = 0.752) according to CAP tertile. Receiver operating characteristic curves for LSM cutoff in diagnosis of F ≥ 2 identified 8.05 kPa for lower CAP tertile, 9.35 kPa for middle, and 10.55 kPa for high tertile. The patients treated with pioglitozone demonstrated decreased LSM values after 1 year of the treatment (*P* \< 0.001), when that in UDCA treated patients did not show significant changes (*P* = 0.068). CAP values did not show significant changes after pioglitazone (*P* = 0.197) or UDCA treatment (*P* = 0.057). When changes in proportion of significant fibrosis (F ≥ 2) were assessed among pioglitazone or UDCA treated patients reflecting CAP values, pioglitazone treated patients demonstrated decrease in proportion of high LSM.

Research conclusions
--------------------

In conclusion, LSM in NASH may overestimate the liver fibrosis stage particularly in patients with high CAP values. Interpretation of LSM considering simultaneously measured CAP scores may provide more helpful information preventing unnecessary liver biopsy in patients with NAFLD.

Research perspectives
---------------------

In patients with NAFLD with high CAP scores, LSM cutoff that leads to liver biopsy may need to be set higher than in those with other chronic liver diseases. Validation studies for more precise LSM cutoffs should be performed incorporating larger number of patients with biopsy proven NAFLD. With more reliable LSM cutoffs for noninvasive diagnosis of liver fibrosis in NAFLD, clinical studies evaluating efficacies of treatment would be more widely preformed in NAFLD.
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